NCT03874299
Completed
Not Applicable
The TOGETHER Project - Transplant Organ Genomics to Help Prevent Rejection in Kidney Transplant Recipients-RNA-seq Signature Validation
ConditionsKidney Transplant Rejection
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Kidney Transplant Rejection
- Sponsor
- Mayo Clinic
- Enrollment
- 302
- Locations
- 1
- Primary Endpoint
- To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients.
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.
Investigators
Mark Stegall
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
- •Adult (\>/=18 years) renal transplant recipient.
- •Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.
Exclusion Criteria
- •Adult (\<18 years) renal transplant recipient.
Outcomes
Primary Outcomes
To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients.
Time Frame: 3 years
The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
The TOGETHER Project - HeartHeart Transplant RejectionNCT03833050Mayo Clinic101
Completed
Not Applicable
The TOGETHER Project - KidneyKidney Transplant RejectionNCT03873623Mayo Clinic250
Completed
Not Applicable
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA DetectionTransplant RejectionAllograft RejectionComplicationsNCT03984747Natera, Inc.110
Terminated
Phase 2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsAcute Lymphoid Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)Hodgkin LymphomaNon-Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT03615105Memorial Sloan Kettering Cancer Center9
Completed
Phase 1
Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet ActionHealthy VolunteersNCT02060396Aragon Institute of Health Sciences24